Maze Therapeutics Quarterly Balance Sheet
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics financial position
As of Jun 30, 2026, Maze Therapeutics reported total assets of $531.6 million, up 75.2% from a year earlier against total liabilities of $78.5 million. Shareholders' equity stood at $453.1 million, or 85.2% of assets. The company held $202.6 million in cash and equivalents against $39.0 million of debt, a net cash position of $163.7 million.
The current ratio (current assets divided by current liabilities) was 18.31, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.09.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 202.64M | 198.77M | 189.25M | 316.77M | 264.54M | 294.37M | 196.81M | 149.61M | 175.06M | 30.02M |
| Short-Term Investments | 208.44M | 153.62M | 152.67M | 67.16M | — | — | — | — | — | — |
| Receivables | — | 20.00M | — | — | — | — | — | — | — | — |
| Total Current Assets | 420.42M | 379.78M | 349.72M | 391.30M | 271.15M | 299.71M | 201.67M | — | — | — |
| Property, Plant & Equipment | 4.39M | 4.68M | 5.04M | 5.54M | 6.01M | 6.31M | 6.67M | — | — | — |
| Long-Term Investments | 83.82M | 10.56M | 18.11M | — | — | — | — | — | — | — |
| Total Assets | 531.63M | 419.71M | 397.13M | 422.06M | 303.52M | 332.84M | 240.54M | — | — | — |
| Accounts Payable | 2.21M | 4.01M | 1.79M | 2.92M | 3.67M | 2.40M | 1.94M | — | — | — |
| Short-Term Debt | 0 | 0 | — | — | — | — | — | — | — | — |
| Total Current Liabilities | 22.96M | 21.24M | 22.56M | 22.11M | 19.90M | 18.62M | 20.67M | — | — | — |
| Long-Term Debt | 38.96M | 38.83M | — | — | — | — | — | — | — | — |
| Total Liabilities | 78.50M | 78.01M | 42.16M | 42.62M | 41.28M | 40.77M | 43.64M | — | — | — |
| Shareholders' Equity | 453.12M | 341.70M | 354.97M | 379.44M | 262.24M | 292.07M | -311.18M | -284.53M | -262.37M | -403.66M |
| Retained Earnings | -558.48M | -513.75M | -489.55M | -454.98M | -424.89M | -391.21M | -358.43M | — | — | — |
| Total Debt | 38.96M | 38.83M | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 372.13M | 313.55M | 341.92M | 383.94M | 264.54M | 294.37M | 196.81M | 149.61M | 175.06M | 30.02M |
| Shares Outstanding | 55.50M | 49.74M | 49.34M | 48.08M | 43.85M | 43.80M | 2.45M | — | — | — |
This table shows 10 quarterly periods of Maze Therapeutics's balance sheet, from Q2 2026 back to Q1 2024, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow MAZE's reporting calendar. What is a balance sheet?